Continuous B cell destruction and regeneration is crucial for effective response to anti CD19 CAR-T cell therapy

被引：0
|
作者：
Nevo, Neta [1 ]
Milman, Neta [1 ]
Cooper, Tim J. [1 ]
Zuckerman, Tsila [2 ]
Shen-Orr, Shai S. [1 ]
机构：
[1] Technnion, Haifa, Israel
[2] Rambam Med Ctr, Haifa, Israel
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
1156 - P1.
引用
收藏
页码：761 / 761
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
    Li, Xin
    Liu, Mei-Jing
    Mou, Nan
    Yang, Zhen-Xing
    Wang, Jia
    Mu, Juan
    Zhu, Hai-Bo
    Deng, Qi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [2] Toxicities of CD19 CAR-T cell immunotherapy
    Hirayama, Alexandre V.
    Turtle, Cameron J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S42 - S49
  • [3] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
    Molostova, Olga
    Shelikhova, Larisa
    Muzalevsky, Yakov
    Kazachenok, Alexey
    Khismatullina, Rimma
    Abugova, Julia
    Kurnikova, Elena
    Trakhtman, Pavel
    Pershin, Dmitry
    Zubachenko, Viktoria
    Fadeeva, Maria
    Popov, Alexander M.
    Illarionova, Olga
    Miakova, Natalia
    Litvinov, Dmitry
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    BLOOD, 2021, 138
  • [4] CD19 CAR-T Cell Therapy: High Efficacy in Autoimmune Diseases
    Brudermanns, Britta
    TRANSFUSIONSMEDIZIN, 2024, 14 (03) : 126 - 126
  • [5] Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
    Zhu, Haibo
    Deng, Haobin
    Mu, Juan
    Lyu, Cuicui
    Jiang, Yanyu
    Deng, Qi
    ONCOTARGETS AND THERAPY, 2021, 14 : 4023 - 4037
  • [6] Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy
    Jain, Michael D.
    Ziccheddu, Bachisio
    Coughlin, Caroline A.
    Faramand, Rawan
    Griswold, Anthony J.
    Reid, Kayla M.
    Landgren, Ola
    Locke, Frederick L.
    Maura, Francesco
    Davila, Marco L.
    Schatz, Jonathan H.
    BLOOD, 2021, 138
  • [7] Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
    Gong, Inna Y.
    Tran, Daisy
    Saibil, Samuel
    Laister, Rob C.
    Kuruvilla, John
    HEMASPHERE, 2024, 8 (08):
  • [8] GENOMIC DRIVERS OF LARGE B-CELL LYMPHOMA RESISTANCE TO CD19 CAR-T THERAPY
    Jain, Michael
    Ziccheddu, Bachisio
    Coughlin, Caroline
    Faramand, Rawan
    Griswold, Anthony
    Reid, Kayla
    Landgren, Ola
    Locke, Frederick
    Maura, Francesco
    Davila, Marco
    Schatz, Jonathan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A703 - A703
  • [9] Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B- Cell Lymphoma
    Luttwak, Efrat
    Flynn, Jessica R.
    Devlin, Sean M.
    Cassanello, Giulio
    Corona, Magdalena
    Dahi, Parastoo B.
    De Abia, Alejandro Luna
    Fein, Joshua
    Giralt, Sergio A.
    Landego, Ivan
    Lin, Richard J.
    Palomba, Maria Lia
    Parascondola, Allison
    Park, Jae H.
    Saldia, Amethyst
    Scordo, Michael
    Tomas, Ana Alarcon
    Shah, Gunjan L.
    Perales, Miguel-Angel
    Salles, Gilles
    Shouval, Roni
    BLOOD, 2023, 142
  • [10] CD19 CAR T cell therapy effective for systemic lupus erythematosus
    Gelfand, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (01) : 4 - 4
12345